zonisamide has been researched along with Benign Essential Tremor in 9 studies
Zonisamide: A benzisoxazole and sulfonamide derivative that acts as a CALCIUM CHANNEL blocker. It is used primarily as an adjunctive antiepileptic agent for the treatment of PARTIAL SEIZURES, with or without secondary generalization.
zonisamide : A 1,2-benzoxazole compound having a sulfamoylmethyl substituent at the 3-position.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Zonisamide at a dose of 25 mg per day did not improve tremor in tremor-dominant PD patients, however, a positive trend was seen as compared to Placebo in the UPDRS tremor score." | 9.51 | Zonisamide add-on in tremor-dominant Parkinson's disease- A randomized controlled clinical trial. ( Bhat, P; Elavarasi, A; Goyal, V; Pandit, AK; Pillai, KS; Prasad, K; Radhakrishnan, DM; Rajan, R; Singh, MB; Srivastava, AK; Srivastava, MP; Vishnu, VY, 2022) |
| "We performed a pilot, crossover trial of zonisamide (ZNS) on essential tremor patients." | 9.11 | Effect of zonisamide on essential tremor: a pilot crossover study in comparison with arotinolol. ( Kondo, T; Miwa, H; Morita, S, 2005) |
| "To assess the effect on functional abilities and the safety profile of zonisamide in adults with essential tremor (ET)." | 8.95 | Zonisamide for essential tremor. ( Bruno, E; Colosimo, C; Filippini, G; Nicoletti, A; Quattrocchi, G; Zappia, M, 2017) |
| "In this evaluator-blinded open-treatment trial, subjects with moderate/severe upper limb essential tremor were titrated to 300 mg/day zonisamide, or adjusted to a lesser dose if symptoms warranted, as monotherapy or as adjunct to stable antitremor medication, followed by a 12-week extension phase." | 7.75 | Zonisamide for essential tremor: an evaluator-blinded study. ( Handforth, A; Kang, GA; Martin, FC; Vanek, Z, 2009) |
| " ZNS was initiated at a dosage of 100 mg/day and escalated to 200 mg/day at day 14." | 6.73 | A double-blind placebo-controlled trial of zonisamide (zonegran) in the treatment of essential tremor. ( Hauser, RA; Sanchez-Ramos, J; Staffetti, JF; Sullivan, KL; Ward, CL; Zesiewicz, TA, 2007) |
| "Zonisamide at a dose of 25 mg per day did not improve tremor in tremor-dominant PD patients, however, a positive trend was seen as compared to Placebo in the UPDRS tremor score." | 5.51 | Zonisamide add-on in tremor-dominant Parkinson's disease- A randomized controlled clinical trial. ( Bhat, P; Elavarasi, A; Goyal, V; Pandit, AK; Pillai, KS; Prasad, K; Radhakrishnan, DM; Rajan, R; Singh, MB; Srivastava, AK; Srivastava, MP; Vishnu, VY, 2022) |
| "We performed a pilot, crossover trial of zonisamide (ZNS) on essential tremor patients." | 5.11 | Effect of zonisamide on essential tremor: a pilot crossover study in comparison with arotinolol. ( Kondo, T; Miwa, H; Morita, S, 2005) |
| "To assess the effect on functional abilities and the safety profile of zonisamide in adults with essential tremor (ET)." | 4.95 | Zonisamide for essential tremor. ( Bruno, E; Colosimo, C; Filippini, G; Nicoletti, A; Quattrocchi, G; Zappia, M, 2017) |
| "In this evaluator-blinded open-treatment trial, subjects with moderate/severe upper limb essential tremor were titrated to 300 mg/day zonisamide, or adjusted to a lesser dose if symptoms warranted, as monotherapy or as adjunct to stable antitremor medication, followed by a 12-week extension phase." | 3.75 | Zonisamide for essential tremor: an evaluator-blinded study. ( Handforth, A; Kang, GA; Martin, FC; Vanek, Z, 2009) |
| " ZNS was initiated at a dosage of 100 mg/day and escalated to 200 mg/day at day 14." | 2.73 | A double-blind placebo-controlled trial of zonisamide (zonegran) in the treatment of essential tremor. ( Hauser, RA; Sanchez-Ramos, J; Staffetti, JF; Sullivan, KL; Ward, CL; Zesiewicz, TA, 2007) |
| "Essential tremor is a common disorder that lacks molecular targets for therapeutic development." | 1.36 | T-type calcium channel antagonists suppress tremor in two mouse models of essential tremor. ( Covey, DF; Handforth, A; Homanics, GE; Krishnan, K; Lee, JY; Martin, FC; Quesada, A; Sakimura, K, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (66.67) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Pillai, KS | 1 |
| Bhat, P | 1 |
| Srivastava, AK | 1 |
| Rajan, R | 1 |
| Radhakrishnan, DM | 1 |
| Elavarasi, A | 1 |
| Srivastava, MP | 1 |
| Singh, MB | 1 |
| Vishnu, VY | 1 |
| Prasad, K | 1 |
| Pandit, AK | 1 |
| Goyal, V | 1 |
| Bruno, E | 1 |
| Nicoletti, A | 1 |
| Filippini, G | 1 |
| Quattrocchi, G | 1 |
| Colosimo, C | 1 |
| Zappia, M | 1 |
| Song, IU | 1 |
| Kim, JS | 1 |
| Lee, SB | 1 |
| Ryu, SY | 1 |
| An, JY | 1 |
| Kim, HT | 1 |
| Kim, YI | 1 |
| Lee, KS | 1 |
| Handforth, A | 2 |
| Martin, FC | 2 |
| Kang, GA | 1 |
| Vanek, Z | 1 |
| Homanics, GE | 1 |
| Covey, DF | 1 |
| Krishnan, K | 1 |
| Lee, JY | 1 |
| Sakimura, K | 1 |
| Quesada, A | 1 |
| Morita, S | 1 |
| Miwa, H | 1 |
| Kondo, T | 1 |
| Sullivan, KL | 2 |
| Ward, CL | 2 |
| Zesiewicz, TA | 2 |
| Hauser, RA | 1 |
| Sanchez-Ramos, J | 1 |
| Staffetti, JF | 1 |
| Bermejo, PE | 1 |
1 review available for zonisamide and Benign Essential Tremor
| Article | Year |
|---|---|
Zonisamide for essential tremor.
Topics: Anticonvulsants; Essential Tremor; Humans; Isoxazoles; Randomized Controlled Trials as Topic; Zonisa | 2017 |
5 trials available for zonisamide and Benign Essential Tremor
| Article | Year |
|---|---|
Zonisamide add-on in tremor-dominant Parkinson's disease- A randomized controlled clinical trial.
Topics: Double-Blind Method; Essential Tremor; Humans; Parkinson Disease; Treatment Outcome; Tremor; Zonisam | 2022 |
Effects of zonisamide on isolated head tremor.
Topics: Adrenergic beta-Antagonists; Aged; Anticonvulsants; Consciousness Disorders; Dose-Response Relations | 2008 |
Effect of zonisamide on essential tremor: a pilot crossover study in comparison with arotinolol.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Anticonvulsants; Cross-Over Studies; Essentia | 2005 |
A double-blind placebo-controlled trial of zonisamide (zonegran) in the treatment of essential tremor.
Topics: Anticonvulsants; Dose-Response Relationship, Drug; Double-Blind Method; Electrophysiology; Equipment | 2007 |
Zonisamide in patients with essential tremor and Parkinson's disease.
Topics: Anticonvulsants; Essential Tremor; Humans; Isoxazoles; Parkinson Disease; Zonisamide | 2007 |
3 other studies available for zonisamide and Benign Essential Tremor
| Article | Year |
|---|---|
Zonisamide for essential tremor: an evaluator-blinded study.
Topics: Aged; Anticonvulsants; Drug Administration Schedule; Essential Tremor; Female; Humans; Isoxazoles; M | 2009 |
T-type calcium channel antagonists suppress tremor in two mouse models of essential tremor.
Topics: Analysis of Variance; Animals; Benzimidazoles; Calcium Channel Blockers; Calcium Channels, T-Type; C | 2010 |
Zonisamide-induced mania in an essential tremor patient.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Essential Tremor; Female; Humans; Isoxazoles; Zonisamide | 2006 |